Management of peripheral neuropathy in diabetes mellitus. Recent research findings and their therapeutic implications.
Peripheral neuropathy in diabetes begins as a physiologic aberration related to hyperglycemia and its subsequent effects of endoneurial hypoxia, elevated sorbitol levels, and decreased myoinositol levels. Resultant decreases in sodium-potassium-adenosine triphosphatase levels ultimately lead to structural alterations at the nodes of Ranvier. Aldose reductase inhibitors and dietary myoinositol supplementation are being used in long-term clinical studies to monitor the possibility that they may prevent or reverse these abnormalities. In the meantime, symptomatic treatment remains the mainstay of management.
Martin
R A
RA
D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000209:etiology; D003929:Diabetic Neuropathies / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D014815:Vitamins / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D014815:Vitamins